Histone reader domain

Histone reader domains are specialized protein modules that recognize and bind to specific post-translational modifications (PTMs) on histone proteins, such as acetylation, methylation, or phosphorylation (Filippakopoulos & Knapp, 2014). These domains, which include bromodomains, chromodomains, and PHD fingers, act as translators of the epigenetic code, recruiting transcriptional machinery and chromatin-remodeling complexes to specific genomic loci to regulate gene expression (Arrowsmith et al., 2012). Dysregulation of these reader proteins is frequently linked to various diseases, particularly cancer, where they can drive the expression of oncogenes like MYC (Muller et al., 2011). Therapeutic strategies often involve small-molecule inhibitors that occupy the binding pocket of the reader domain, effectively blocking its interaction with histones and silencing pathogenic gene programs (Shortt et al., 2017). Clinical development has primarily focused on Bromodomain and Extra-Terminal (BET) family inhibitors for oncology and inflammatory indications, though challenges such as dose-limiting toxicities remain (Fujisawa & Filippakopoulos, 2017).

Other names

Epigenetic reader domainChromatin reader domainHistone-binding modulePTM reader

Small molecule inhibitors competitively bind to the hydrophobic pocket of the reader domain, preventing its interaction with specific post-translational modifications (such as acetylated or methylated lysine residues) on histone tails, thereby disrupting the recruitment of transcriptional machinery (Filippakopoulos & Knapp, 2014).